摘要
目的探讨Pax2和E—cadherin在9口巢浆液性肿瘤中的表达及临床意义。方法采用免疫组织化学EnVision两步法检测10例正常卵巢组织、10例卵巢良性浆液性肿瘤、28例交界性浆液性肿瘤、72例浆液性腺癌中Pax2和E-cadherin的表达情况，并分析其表达与浆液性腺癌的临床分期和组织学分级的关系。结果（1）Pax2和E—cadherin在正常卵巢组织、良性浆液性肿瘤、交界性浆液性肿瘤及浆液性腺癌中的阳性表达率分别为：0、40．0％、64．3％、77．8％和0、10．0％、71．4％、55．6％．Pax2和E—cad—herin的阳性率在4组间比较，差异均有统计学意义（均P〈0．05）。（2）Pax2在浆液性腺癌中的表达率随临床分期、病理分级的升高而增加，差异有统计学意义（P〈O．05）；E-cadherin在浆液性腺癌中的表达率随临床分期的升高而下降，差异有统计学意义（P〈0．05）。表达率随病理分级的升高有下降趋势，但差异无统计学意义（P〉0．05）。结论Pax2和E—cadherin的表达可能从正常卵巢组织、良性浆液性肿瘤、交界性浆液性肿瘤到浆液性腺癌的发生及演变过程中起促进作用；在浆液性腺癌中，Pax2的高表达和E—cadherin的低表达可能与浆液性腺癌的侵袭和转移有关，提示联合检测Pax2和E-cadherin对判断浆液性腺癌的恶性程度和临床预后的评估有指导意义。
Objective To investigate the expression and clinical significance of Pax2 and E-cadherin in ovarian serous tumor. Methods Pax2 and E-cadherin were examined by immunohistochemistry （EnVision method） in 10 samples from normal ovarian tissue, 10 from ovarian serous adenoma, 28 from ovarian serous borderline tumor and 72 from ovarian serous adenocarci- noma. The correlation of Pax2 and E-cadherin expression with clinical stage, pathological grade of serous adenocarcinoma were analyzed. Results The positive expression rates of Pax2 and E-caclherin in normal ovarian tissue, ovarian serous adenoma, o- varian serous borderline tumor and ovarian serous adenocarcinoma were O, 40.0%, 64.3%, 77.8% and 0, 10.0%, 71.4%, 55.6%, respectively （P〈0.05）. The expression rate of Pax2 in serous adenocarcinoma was increased with the rising of clinical stage and pathological grade of the tumor （P〈0.05）; while the expression rate of E-cadherin in serous adenocarcinoma was decreased with the rising of clinical stage（P〈0.05）. Conclusion The expression of Pax2 and E-cadherin may be involved in evolution from nor- mal ovarian tissue, ovarian serous adenoma, ovarian serous borderline tumor to ovarian serous adenocarcinoma. In serous ade- nocarcinoma the high expression of Pax2 and low expression of E-cadherin may have correlation with the invasion and metasta- sis of serous adenocarcinoma, indicating that the combined detection of Pax2 and E-cadherin may of value in judgment the ma- lignancy and clinic prognosis of serous adenocarcinoma.
出处
《浙江医学》
CAS
2013年第1期10-13,共4页
Zhejiang Medical Journal
